These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1782306)

  • 21. Famotidine 40mg B.I.D. in the treatment of reflux oesophagitis.
    Ahmed W; Qureshi H; Alam SE; Zuberi SJ
    J Pak Med Assoc; 1995 Sep; 45(9):241-3. PubMed ID: 8683830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
    Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nizatidine versus placebo in gastro-oesophageal reflux disease: a 12-week, multicentre, randomised, double-blind study.
    Cloud ML; Offen WW; Robinson M
    Br J Clin Pract Suppl; 1994 Nov; 76():3-10. PubMed ID: 7794701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group.
    Simon TJ; Berlin RG; Tipping R; Gilde L
    Scand J Gastroenterol; 1993 May; 28(5):375-80. PubMed ID: 8511496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial.
    Orenstein SR; Shalaby TM; Devandry SN; Liacouras CA; Czinn SJ; Dice JE; Simon TJ; Ahrens SP; Stauffer LA
    Aliment Pharmacol Ther; 2003 May; 17(9):1097-107. PubMed ID: 12752346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis.
    Ohara S; Haruma K; Kinoshita Y; Kusano M
    J Gastroenterol; 2010 Dec; 45(12):1219-27. PubMed ID: 20632193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
    Bochenek WJ; Mack ME; Fraga PD; Metz DC
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1105-14. PubMed ID: 15569113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease.
    Engzelius JM; Solhaug JH; Knapstad LJ; Kjaersgaard P
    Scand J Gastroenterol; 1997 Jun; 32(6):513-8. PubMed ID: 9200279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
    Taha AS; McCloskey C; Prasad R; Bezlyak V
    Lancet; 2009 Jul; 374(9684):119-25. PubMed ID: 19577798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease.
    Palmer RH; Frank WO; Rockhold FW; Wetherington JD; Young MD
    J Clin Gastroenterol; 1990; 12 Suppl 2():S29-34. PubMed ID: 2246493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
    Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
    Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
    Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
    Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
    Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
    Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients.
    Zacny J; Zamakhshary M; Sketris I; Veldhuyzen van Zanten S
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1299-312. PubMed ID: 15932360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
    Richter JE; Campbell DR; Kahrilas PJ; Huang B; Fludas C
    Arch Intern Med; 2000 Jun; 160(12):1803-9. PubMed ID: 10871974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis.
    Nakamura T; Shirakawa K; Masuyama H; Sugaya H; Hiraishi H; Terano A
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():19-26. PubMed ID: 15943842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.
    Karkon Varnosfaderani S; Hashem-Dabaghian F; Amin G; Bozorgi M; Heydarirad G; Nazem E; Nasiri Toosi M; Mosavat SH
    J Integr Med; 2018 Mar; 16(2):126-131. PubMed ID: 29526236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.